CA2000082A1 - Methode de detection de cellules tumorales multipharmacoresistantes et sondes de verapamil utilisees en association avec cette methode - Google Patents

Methode de detection de cellules tumorales multipharmacoresistantes et sondes de verapamil utilisees en association avec cette methode

Info

Publication number: CA2000082A1
Authority: CA; Canada
Prior art keywords: derivative; verapamil; polypeptide; sample; concentration
Prior art date: 1988-10-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2000082

Other languages

English (en)

Inventor

Ahmad R. Safa

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

REESE (MICHAEL) HOSPITAL AND MEDICAL CENTER

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-03

Filing date

1989-10-03

Publication date

1990-04-03

1989-10-03 Application filed by Individual filed Critical Individual

1990-04-03 Publication of CA2000082A1 publication Critical patent/CA2000082A1/fr

Status Abandoned legal-status Critical Current

Links

SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 title claims abstract description 94
238000000034 method Methods 0.000 title claims abstract description 62
239000003814 drug Substances 0.000 title claims abstract description 37
229940079593 drug Drugs 0.000 title claims abstract description 36
210000004881 tumor cell Anatomy 0.000 title claims abstract description 16
229960001722 verapamil Drugs 0.000 title claims description 69
238000001514 detection method Methods 0.000 title abstract description 9
239000000523 sample Substances 0.000 title description 13
206010028980 Neoplasm Diseases 0.000 claims abstract description 41
230000001413 cellular effect Effects 0.000 claims abstract description 19
239000000463 material Substances 0.000 claims abstract description 13
238000009007 Diagnostic Kit Methods 0.000 claims abstract description 4
229920001184 polypeptide Polymers 0.000 claims description 49
-1 N-(p-azidosalicyl)aminomethyl verpamil Chemical compound 0.000 claims description 37
210000004027 cell Anatomy 0.000 claims description 34
108090000765 processed proteins & peptides Proteins 0.000 claims description 32
102000004196 processed proteins & peptides Human genes 0.000 claims description 32
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 31
230000015572 biosynthetic process Effects 0.000 claims description 17
150000001875 compounds Chemical class 0.000 claims description 17
239000003446 ligand Substances 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 16
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 12
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 10
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 7
229960004528 vincristine Drugs 0.000 claims description 7
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 7
206010048723 Multiple-drug resistance Diseases 0.000 claims description 6
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 6
239000002246 antineoplastic agent Substances 0.000 claims description 6
238000000376 autoradiography Methods 0.000 claims description 6
229940127089 cytotoxic agent Drugs 0.000 claims description 6
229960003048 vinblastine Drugs 0.000 claims description 6
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 6
238000002372 labelling Methods 0.000 claims description 5
JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical group CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 claims description 5
239000012528 membrane Substances 0.000 claims description 4
230000001678 irradiating effect Effects 0.000 claims description 3
150000003254 radicals Chemical class 0.000 claims description 3
229940009456 adriamycin Drugs 0.000 claims description 2
238000005119 centrifugation Methods 0.000 claims description 2
238000000926 separation method Methods 0.000 claims 1
238000003786 synthesis reaction Methods 0.000 abstract description 13
238000011534 incubation Methods 0.000 abstract 1
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 19
230000002285 radioactive effect Effects 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 8
239000002904 solvent Substances 0.000 description 8
238000004809 thin layer chromatography Methods 0.000 description 8
238000005222 photoaffinity labeling Methods 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
LMUISDJVRQDLEK-UHFFFAOYSA-N 6,7-dichloro-1-[(3,4-dimethoxyphenyl)methyl]isoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(Cl)=C(Cl)C=C12 LMUISDJVRQDLEK-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
238000010265 fast atom bombardment Methods 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
229940127291 Calcium channel antagonist Drugs 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
238000000862 absorption spectrum Methods 0.000 description 4
238000003556 assay Methods 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000000480 calcium channel blocker Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000003118 drug derivative Substances 0.000 description 4
230000003993 interaction Effects 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
229930014626 natural product Natural products 0.000 description 4
LWAVGNJLLQSNNN-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-azidobenzoate Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C(=O)ON1C(=O)CCC1=O LWAVGNJLLQSNNN-UHFFFAOYSA-N 0.000 description 3
CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
229960001338 colchicine Drugs 0.000 description 3
229960004679 doxorubicin Drugs 0.000 description 3
230000036457 multidrug resistance Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
RBAFCMJBDZWZIV-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-azido-2-hydroxybenzoate Chemical compound OC1=CC(N=[N+]=[N-])=CC=C1C(=O)ON1C(=O)CCC1=O RBAFCMJBDZWZIV-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
108010090054 Membrane Glycoproteins Proteins 0.000 description 2
102000012750 Membrane Glycoproteins Human genes 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
206010034133 Pathogen resistance Diseases 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
239000003431 cross linking reagent Substances 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
229940093499 ethyl acetate Drugs 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
238000001914 filtration Methods 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
239000003269 fluorescent indicator Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
238000011533 pre-incubation Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
NKUZQMZWTZAPSN-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-bromoacetate Chemical compound BrCC(=O)ON1C(=O)CCC1=O NKUZQMZWTZAPSN-UHFFFAOYSA-N 0.000 description 1
NGXDNMNOQDVTRL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(4-azido-2-nitroanilino)hexanoate Chemical compound [O-][N+](=O)C1=CC(N=[N+]=[N-])=CC=C1NCCCCCC(=O)ON1C(=O)CCC1=O NGXDNMNOQDVTRL-UHFFFAOYSA-N 0.000 description 1
KWBGHMPXFVRHOV-UHFFFAOYSA-N 1-[(5-azido-2-nitrophenyl)methoxy]pyrrolidine-2,5-dione Chemical compound [O-][N+](=O)C1=CC=C(N=[N+]=[N-])C=C1CON1C(=O)CCC1=O KWBGHMPXFVRHOV-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
DPNFPNYMPUQQRZ-UHFFFAOYSA-N 2-azidooxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1ON=[N+]=[N-] DPNFPNYMPUQQRZ-UHFFFAOYSA-N 0.000 description 1
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
SWMHKFTXBOJETC-UHFFFAOYSA-N Azidopine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCNC(=O)C=2C=CC(=CC=2)N=[N+]=[N-])C1C1=CC=CC=C1C(F)(F)F SWMHKFTXBOJETC-UHFFFAOYSA-N 0.000 description 1
229940122642 Calcium channel agonist Drugs 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
230000008955 bacterial trafficking Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
MHFFHHOWVDJOSC-UHFFFAOYSA-N benzoyloxy(diazonio)azanide Chemical compound [N-]=[N+]=NOC(=O)C1=CC=CC=C1 MHFFHHOWVDJOSC-UHFFFAOYSA-N 0.000 description 1
UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
229960003665 bepridil Drugs 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000000801 calcium channel stimulating agent Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000001085 differential centrifugation Methods 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
239000012039 electrophile Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000009061 membrane transport Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
QCWXZFZXEGTLOV-UHFFFAOYSA-N n-propan-2-ylpentan-1-amine Chemical compound CCCCCNC(C)C QCWXZFZXEGTLOV-UHFFFAOYSA-N 0.000 description 1
229960001783 nicardipine Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
229960000715 nimodipine Drugs 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
239000007856 photoaffinity label Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
229960001989 prenylamine Drugs 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940108519 trasylol Drugs 0.000 description 1
ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
229960002324 trifluoperazine Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000007039 two-step reaction Methods 0.000 description 1
229960000881 verapamil hydrochloride Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Pathology (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmacology & Pharmacy (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
Peptides Or Proteins (AREA)

CA 2000082 1988-10-03 1989-10-03 Methode de detection de cellules tumorales multipharmacoresistantes et sondes de verapamil utilisees en association avec cette methode Abandoned CA2000082A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25274688A	1988-10-03	1988-10-03
US252,746		1988-10-03

Publications (1)

Publication Number	Publication Date
CA2000082A1 true CA2000082A1 (fr)	1990-04-03

Family

ID=22957359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2000082 Abandoned CA2000082A1 (fr)	1988-10-03	1989-10-03	Methode de detection de cellules tumorales multipharmacoresistantes et sondes de verapamil utilisees en association avec cette methode

Country Status (3)

Country	Link
AU (1)	AU4518889A (fr)
CA (1)	CA2000082A1 (fr)
WO (1)	WO1990004177A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1258273B (it) *	1992-04-06	1996-02-22	Anna Maria Villa	Metodo per la determinazione della resistenza multidroga in cellule viventi.
US5436243A (en) *	1993-11-17	1995-07-25	Research Triangle Institute Duke University	Aminoanthraquinone derivatives to combat multidrug resistance
FR2729569B1 (fr) *	1995-01-19	1997-07-25	Consultants Internationaux Sur	Compositions pharmaceutiques utiles pour la reversion de la resistance multiple aux drogues
WO1998004250A1 (fr) *	1996-07-25	1998-02-05	Consultants Internationaux Sur Le Medicament (S.A.R.L.)	Compositions pharmaceutiques utiles pour la reversion de la resistance multiple aux drogues
KR20020045445A (ko) *	2000-12-11	2002-06-19	최철희	독소루비신 내성 급성 골수성 백혈병 아세포주를 이용한내성억제물질과 반응성 산소종 생성 세포독성물질의선별방법

1989
- 1989-10-03 AU AU45188/89A patent/AU4518889A/en not_active Abandoned
- 1989-10-03 CA CA 2000082 patent/CA2000082A1/fr not_active Abandoned
- 1989-10-03 WO PCT/US1989/004394 patent/WO1990004177A1/fr not_active Ceased

Also Published As

Publication number	Publication date
AU4518889A (en)	1990-05-01
WO1990004177A1 (fr)	1990-04-19

Publication	Publication Date	Title
US5464741A (en)	1995-11-07	Palladium (II) octaethylporphine alpha-isothiocyanate as a phosphorescent label for immunoassays
JP3009170B2 (ja)	2000-02-14	薬物の検出用試剤
DE3750503T2 (de)	1995-02-09	Chemilumineszierende Acridinium- und Phenantridiniumsalze.
US5352803A (en)	1994-10-04	5(6)-methyl substituted fluorescein derivatives
US4665022A (en)	1987-05-12	Bioluminescent assay reagent and method
EP0107134B1 (fr)	1986-04-09	Immunogènes à base de substances actives antidépressives et tricycliques, anticorps, conjugués marqués et dérivés apparentés
JP4435305B2 (ja)	2010-03-17	トピラメートのイムノアッセイ、並びに類似体及び抗体
Wani et al.	1984	Antibodies to UV irradiated DNA: the monitoring of DNA damage by ELISA and indirect immunofluorescence
JPH0137693B2 (fr)	1989-08-09
US5468854A (en)	1995-11-21	Characterization of specific drug receptors with fluorescent ligands
SE447026B (sv)	1986-10-20	Forfarande for immunologisk bestemning
EP1105730B1 (fr)	2008-01-23	Immunoessai base sur l'inhibition enzymatique
JP4990785B2 (ja)	2012-08-01	トピラメートに関する免疫アッセイ
Riceberg et al.	1974	Radioimmunoassays of 3, 4, 5-trimethoxyphenethylamine (mescaline) and 2, 5-dimethoxy-4-methylphenyl-isopropylamine (DOM)
RU2025734C1 (ru)	1994-12-30	Способ обнаружения опухолевого маркера rsp в жидкостях тела, способ обнаружения злокачественности, зонд для избирательного связывания с опухолевым маркером rsp
CA2000082A1 (fr)	1990-04-03	Methode de detection de cellules tumorales multipharmacoresistantes et sondes de verapamil utilisees en association avec cette methode
JPS59108959A (ja)	1984-06-23	ヒスタミン定量法
US5516647A (en)	1996-05-14	Compounds useful as alkaline phosphatase inhibitors and therapeutic agents
WO1997011371A1 (fr)	1997-03-27	Detection et quantification de la 8-hydroxy-adenine avec des anticorps monoclonaux
US5053336A (en)	1991-10-01	Monoclonal antibodies for the separate detection of halodeoxyuridines and method for their use
EP0226730B1 (fr)	1994-03-02	Composés et essai immunologique pour antidépressifs tricycliques
US4997771A (en)	1991-03-05	Method for measuring the BZ-1 receptor binding activity in a test sample or test compound
WO1991002084A1 (fr)	1991-02-21	Procede de detection et de traitement de cellules tumorales resistant a des medicaments multiples, et sondes utiles de derives de colchicine
US4765972A (en)	1988-08-23	Vinca alkaloid photoactive analogs and their uses
Estas et al.	1973	Simultaneous determination of 5, 5-diphenylhydantoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin in serum, urine and tissues by gas—liquid chromatography after flash-heater methylation

Legal Events

Date	Code	Title	Description
1992-04-05	FZDE	Dead